Definitive diagnosis of WDPMT was established through comprehensive immunohistochemistry (retained BAP1 expression) and next-generation sequencing, which revealed a low tumor mutational burden and a pathogenic GPR124 mutation. The gene discussed is BAP1; the disease is neoplasm.